95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Johanne Elise Nyen1*
Anja Ødegård Booth2†
Øyvind Husby2Christoffer Bugge1
Ingrid Engebretsen1Francisco Oteiza1
Åslaug Helland3,4Lars Fjellbirkeland3,5
Odd Terje Brustugun3,6Bjørn Henning Grønberg7,8- 1Oslo Economics, Oslo, Norway
- 2Pfizer AS, Oslo, Norway
- 3Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- 4Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway
- 5Department of Respiratory Medicine, Oslo University Hospital, Oslo, Norway
- 6Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway
- 7Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
- 8Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
A Corrigendum on
Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study
by Nyen JE, Booth AØ, Husby Ø, Bugge C, Engebretsen I, Oteiza F, Helland Å, Fjellbirkeland L, Brustugun OT and Grønberg BH (2025). Front. Oncol. 15:1506041. doi: 10.3389/fonc.2025.1506041
In the published article, there was an error. The ClinicalTrials.gov-identifier of our study was not included in the publication.
A correction has been made to Materials and methods, Reporting guidelines and ethics, Paragraph 1. This sentence previously stated:
“The study was approved by the Regional Ethics Committee of Norway South-East D (Reference number 485084)”.
The corrected sentence appears below:
“The study was approved by the Regional Ethics Committee of Norway South-East D (Reference number 485084) and registered at http://ClinicalTrials.gov (Reference number NCT05834348)”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: ROS, ALK, EGFR, real world data, lung cancer, time on treatment
Citation: Nyen JE, Booth AØ, Husby Ø, Bugge C, Engebretsen I, Oteiza F, Helland Å, Fjellbirkeland L, Brustugun OT and Grønberg BH (2025) Corrigendum: Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study. Front. Oncol. 15:1595028. doi: 10.3389/fonc.2025.1595028
Received: 17 March 2025; Accepted: 18 March 2025;
Published: 26 March 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Nyen, Booth, Husby, Bugge, Engebretsen, Oteiza, Helland, Fjellbirkeland, Brustugun and Grønberg. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Johanne Elise Nyen, amVuQG9zbG9lY29ub21pY3Mubm8=
†Present address: Anja Ødegård Booth, AstraZeneca AS, Oslo, Norway